Nova Eye Medical Limited (ASX:EYE)

Nova Eye Medical Financials Overview

Financials in millions AUD. Fiscal year is July - June.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue Revenue Growth	33.05	29.27	23.33	17.03	13.38	13.39
Revenue Growth	12.94%	25.47%	37.00%	27.26%	-0.12%	4.51%
Gross Profit Gross Profit Growth	22.05	18.89	16.83	14.39	11.09	11.15
Operating Income Operating Income Growth	-7.07	-8.99	-8.97	-11.78	-9.7	-4.97
Net Income Net Income Growth	-7.03	-9.06	-8.79	-15.29	-7.5	-4.36
Earnings Per Share EPS Growth	-0.03	-0.04	-0.04	-0.10	-0.05	-0.03
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
AlphaRET AlphaRET Growth	-	0.19	0.17	0.36	0.24	0.31
Glaucoma Surgical Devices Glaucoma Surgical Devices Growth	32.95	29.08	23.16	16.66	13.14	13.09
Total Total Growth	33.05	29.27	23.33	17.03	13.38	13.39

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Investments Cash & Investments Growth	2.62	5.06	6.15	7.42	8	17.8
Total Debt Total Debt Growth	2.79	3.02	3.35	1.53	1.94	3.7
Net Cash (Debt) Net Cash Growth	-0.17	2.04	2.8	5.89	6.06	14.1
Net Cash Growth	-	-27.27%	-52.41%	-2.79%	-57.05%	-84.72%
Net Cash Per Share Net Cash Per Share Growth	-0.00	0.01	0.01	0.04	0.04	0.10

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Cash Flow Operating Cash Flow Growth	-4.87	-6.15	-7.86	-6.82	-4.72	-13.14
Capital Expenditures CapEx Growth	-0.34	-0.3	-0.21	-0.26	-0.13	-0.38
Free Cash Flow Free Cash Flow Growth	-5.21	-6.45	-8.07	-7.09	-4.85	-13.53
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Gross Margin	66.71%	64.54%	72.15%	84.55%	82.89%	83.25%
Operating Margin	-21.40%	-30.70%	-38.47%	-69.19%	-72.50%	-37.07%
Pretax Margin	-21.27%	-30.95%	-37.68%	-99.86%	-58.43%	-39.20%
Profit Margin	-21.27%	-30.95%	-37.69%	-89.83%	-56.03%	-32.52%
FCF Margin	-15.77%	-22.03%	-34.59%	-41.63%	-36.27%	-100.99%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 8, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Forward PE	-	297.83	297.83	297.83	297.83	297.83
PS Ratio	1.34	1.07	2.16	2.96	2.01	3.43

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 8, 2026

Data Sources Report a data error